litlas
Log inCreate account

Andreas Neubauer

Active 1987–2025

150
Papers
21,225
Citations
79
h-index
138
i10-index

Citations

Citations per year for Andreas Neubauer1979: 3 citations1988: 3 citations1990: 1 citations1991: 7 citations1992: 16 citations1993: 12 citations1994: 20 citations1995: 18 citations1996: 16 citations1997: 21 citations1998: 16 citations1999: 27 citations2000: 39 citations2001: 54 citations2002: 82 citations2003: 102 citations2004: 96 citations2005: 151 citations2006: 98 citations2007: 134 citations2008: 140 citations2009: 122 citations2010: 158 citations2011: 131 citations2012: 129 citations2013: 127 citations2014: 141 citations2015: 126 citations2016: 138 citations2017: 154 citations2018: 133 citations2019: 503 citations2020: 629 citations2021: 667 citations2022: 548 citations2023: 470 citations2024: 596 citations2025: 240 citations2026: 12 citations1980–1987: no citations, so these years are not shown1989: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,878 citing papers, 23.1% of this breakdownGermany: 983 citing papers, 12.1% of this breakdownItaly: 516 citing papers, 6.4% of this breakdownUnited Kingdom: 506 citing papers, 6.2% of this breakdownChina: 493 citing papers, 6.1% of this breakdownFrance: 449 citing papers, 5.5% of this breakdownJapan: 246 citing papers, 3% of this breakdownSpain: 244 citing papers, 3% of this breakdownNetherlands: 230 citing papers, 2.8% of this breakdownAustralia: 227 citing papers, 2.8% of this breakdownCanada: 207 citing papers, 2.6% of this breakdownSwitzerland: 202 citing papers, 2.5% of this breakdown
0%23.1%Other 23.9%

Institutions

Fields

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology9.8%
  • Immunology and Microbiology6.3%
  • Mathematics4.4%
  • Engineering1.8%
  • Computer Science1.6%
  • Other2.2%

Topics

  • Acute Myeloid Leukemia Research11.8%
  • Chronic Myeloid Leukemia Treatments7.2%
  • Chronic Lymphocytic Leukemia Research4.4%
  • Hematopoietic Stem Cell Transplantation3.9%
  • Lymphoma Diagnosis and Treatment3.8%
  • Acute Lymphoblastic Leukemia research3.2%
  • Other65.7%

Coauthors

All papers

Open in search
  1. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

    Authors: Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R. Baer, Richard A. Larson, Celalettin Üstün, Francesco Fabbiano, Harry P. Erba, Antonio Di Stasi, Robert K. Stuart, Rebecca L. Olin, Margaret Kasner, Fabio Ciceri, Wen‐Chien Chou, Nikolai A. Podoltsev, Christian Récher, Hisayuki Yokoyama, Naoko Hosono, Sung‐Soo Yoon, Je‐Hwan Lee, Timothy S. Pardee, Amir T. Fathi, Chaofeng Liu, Nahla Hasabou, Xuan Liu, Erkut Bahceci, Mark J. Levis - New England Journal of Medicine 2019 cited by 1,239

  2. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

    Authors: Andreas Burchert, Gesine Bug, Lea Fritz, Jürgen Finke, Matthias Stelljes, Christoph Röllig, Ellen Wollmer, Ralph Wäsch, Martin Bornhäuser, Tobias Berg, Fabian Lang, Gerhard Ehninger, Hubert Serve, Robert Zeiser, Eva-Maria Wagner, Nicolaus Kröger, Christine Wolschke, Michael Schleuning, Katharina S. Götze, Christoph Schmid, Martina Crysandt, Eva Eßeling, Dominik Wolf‎, Ying Wang, Alexandra Böhm, Christian Thiede, Torsten Haferlach, Christian Michel, Wolfgang Bethge, Thomas Wündisch, Christian Brandts, Susanne Harnisch, Michael Wittenberg, Heinz‐Gert Hoeffkes, Susanne Rospleszcz, Alexander Burchardt, Andreas Neubauer, Markus Brugger, Konstantin Strauch, Carmen Schade‐Brittinger, Stephan Metzelder - Journal of Clinical Oncology 2020 cited by 551

  3. Iterative Regularization Methods for Nonlinear Ill-Posed Problems

    Authors: Barbara Kaltenbacher, Andreas Neubauer, Otmar Scherzer - DAGLIB 2008 cited by 796

  4. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

    Authors: Franziska Taube, Julia Annabell Georgi, Michael Krämer, Sebastian Stasik, Jan Moritz Middeke, Christoph Röllig, Utz Krug, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Tim H. Brümmendorf, Ralph Naumann, A. Petzold, Roger Mulet‐Lazaro, Peter J.M. Valk, Björn Steffen, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schäfer‐Eckart, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Richard Noppeney, Ulrich Kaiser, Claudia D. Baldus, Martin Kaufmann, Sylvia Herold, Friedrich Stölzel, Katja Sockel, Malte von Bonin, Carsten Müller‐Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL) - Blood 2021 cited by 164

  5. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

    Authors: Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, Catherine C. Smith, Mark R. Litzow, Maria R. Baer, David F. Claxton, Harry P. Erba, Stan Gill, Stuart L. Goldberg, Joseph G. Jurcic, Richard A Larson, Chaofeng Liu, Ellen K. Ritchie, Gary J. Schiller, Alexander I. Spira, Stephen A. Strickland, Raoul Tibes, Celalettin Üstün, Eunice S. Wang, Robert K. Stuart, Christoph Röllig, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark J. Levis - The Lancet Oncology 2017 cited by 488

  6. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Authors: for the SAKK and the German CML Study Group, Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele, Markus Pfirrmann, Stefan W. Krause, Hans‐Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, C. Nerl, Aloïs Gratwohl, Gabriela M. Baerlocher, Dominik Heim, Tim H. Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Marcus Müller, Sabine Jeromin, Ulrike Proetel, Katharina Kohlbrenner, Astghik Voskanyan, Sébastien Rinaldetti, Wolfgang Seifarth, Birgit Spieß, Leopold Balleisen, M-E Goebeler, Mathias Hänel, Anthony D. Ho, Jolanta Dengler, Christiane Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, H. W. Lindemann, Cornelius F. Waller, M. Pfreundschuh, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiřı́ Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland J. Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, W. Gaßmann, Antonio Pezzutto, Michael Schenk, Peter Brossart, Thomas Geer, Stephan Bildat, E. Schäfer, Andreas Hochhaus, Joerg Hasford - Leukemia 2017 cited by 339

  7. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

    Authors: Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen A. Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Récher, Sung‐Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee‐Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramón V. Tiu, Mark J. Levis - Blood 2022 cited by 137

  8. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

    Authors: Robert Zeiser, Andreas Burchert, Claudia Lengerke, Mareike Verbeek, Kristina Maas‐Bauer, Stephan Metzelder, Silvia Spoerl, Markus Ditschkowski, Matyas Ecsedi, Katja Sockel, Francis Ayuk, Salem Ajib, Flore Sicre de Fontbrune, Il‐Kang Na, Livius Penter, Udo Holtick, Dominik Wolf‎, Esther Schuler, Everett Meyer, Petya Apostolova, Hartmut Bertz, Reinhard Marks, Michael Lübbert, Ralph Wäsch, Christof Scheid, Friedrich Stölzel, Rainer Ordemann, Gesine Bug, Guido Kobbe, Robert S. Negrin, Mats Brune, Alexandros Spyridonidis, A Schmitt-Gräff, Walter J. F. M. van der Velden, Gerwin Huls, Stephan Mielke, Goetz Ulrich Grigoleit, Jürgen Kuball, Ryan Flynn, Gabriele Ihorst, Jing Du, Bruce R. Blazar, R. Arnold, Nicolaus Kröger, Jakob Passweg, Jörg Halter, G. Socié, Dietrich W. Beelen, Christian Peschel, Andreas Neubauer, Jürgen Finke, Justus Duyster, Nikolas von Bubnoff - Leukemia 2015 cited by 540

  9. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

    Authors: Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer, Gerhard Ehninger, Thomas Illmer - Blood 2002 cited by 1,729

  10. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    Authors: Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller‐Tidow, Utz Krug, Claudia D. Baldus, Christian Brandts, Volker Kunzmann, Hermann Einsele, Alwin Krämer, Kerstin Schäfer‐Eckart, Andreas Neubauer, Andreas Burchert, Aristoteles Giagounidis, Stefan W. Krause, Andréas Mackensen, Walter E. Aulitzky, Regina Herbst, Mathias Hänel, Alexander Kiani, Norbert Frickhofen, Johannes Kullmer, Ulrich Kaiser, Hartmut Link, Thomas Geer, A. Reichle, Christian Junghanß, Roland Repp, Frank Heits, Heinz Dürk, Jana Hase, Ina‐Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Johannes Schetelig, Michael Krämer, Wolfgang E. Berdel, Gerhard Ehninger - The Lancet Oncology 2015 cited by 400

  11. Ambulatory assessment for physical activity research: State of the science, best practices and future directions

    Authors: Markus Reichert, Marco Giurgiu, Elena D. Koch, Lena M. Wieland, Sven Lautenbach, Andreas Neubauer, Birte von Haaren‐Mack, René Schilling, Irina Timm, Nanna Notthoff, Isabel Marzi, Holger Hill, Sarah Brüßler, Tobias Eckert, Janis Fiedler, Alexander Burchartz, Bastian Anedda, Kathrin Wunsch, Markus Gerber, Darko Jekauc, Alexander Wöll, Genevieve F. Dunton, Martina Kanning, Claudio R. Nigg, Ulrich Ebner‐Priemer, Yue Liao - Psychology of sport and exercise 2020 cited by 178

  12. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

    Authors: Viola Poeschel, Gerhard Held, Marita Ziepert, Mathias Witzens‐Harig, Harald Holte, Lorenz Thurner, Peter Borchmann, Andreas Viardot, Martin Soekler, Ulrich Keller, Christian Schmidt, Lorenz Truemper, Rolf Mahlberg, Reinhard Marks, Heinz‐Gert Hoeffkes, Bernd Metzner, Judith Dierlamm, Norbert Frickhofen, Mathias Haenel, Andreas Neubauer, Michael Kneba, Francesco Merli, Alessandra Tucci, Peter de Nully Brown, Massimo Federico, Eva Lengfelder, Alice Di Rocco, Ralf Ulrich Trappe, Andreas Rosenwald, Christian Berdel, Martin Maisenhoelder, Ofer Shpilberg, Josif Amam, Konstantinos Christofyllakis, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Maike Nickelsen, Gerald Wulf, Bertram Glaß, Norbert Schmitz, Bettina Altmann, Markus Loeffler, Michael Pfreundschuh - The Lancet 2019 cited by 253

  13. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

    Authors: Maria‐Luisa Schubert, Anita Schmitt, Angela Hückelhoven‐Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp‐Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas E. Kulozik, Joachim B. Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann W. Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper, Martin Görner, Jürgen Finke, Andreas Neubauer, Mark Ringhoffer, Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt - Journal of Hematology & Oncology 2023 cited by 36

  14. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

    Authors: Christoph Röllig, Michael Krämer, Christoph Schliemann, Jan‐Henrik Mikesch, Björn Steffen, Alwin Krämer, Richard Noppeney, Kerstin Schäfer‐Eckart, Stefan W. Krause, Mathias Hänel, Regina Herbst, Volker Kunzmann, Hermann Einsele, Edgar Jost, Tim H. Brümmendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Kristina Sohlbach, Lars Fransecky, Martin Kaufmann, Dirk Niemann, Markus Schaich, Norbert Frickhofen, Alexander Kiani, Frank Heits, Ulrich Krümpelmann, Ulrich Kaiser, Johannes Kullmer, Maxi Wass, Friedrich Stölzel, Malte von Bonin, Jan Moritz Middeke, Christian Thiede, Johannes Schetelig, Wolfgang E. Berdel, Gerhard Ehninger, Claudia D. Baldus, Carsten Müller‐Tidow, Uwe Platzbecker, Hubert Serve, Martin Bornhäuser - Blood 2020 cited by 135

  15. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

    Authors: Michael Lübbert, Pierre W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, Laimonas Griškevičius, Andreas Neubauer, Martina Crysandt, Radovan Vrḫovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Olivier Legrand, Robin Foà, Gianluca Gaïdano, Daniëlle van Lammeren‐Venema, Eduardus F. M. Posthuma, Mels Hoogendoorn, Anne Giraut, Marian Stevens‐Kroef, Joop H. Jansen, Aniek O. de Graaf, Fabio Efficace, Emanuele Ammatuna, Jean‐Pierre Vilque, Ralph Wäsch, Heiko Becker, Nicole M. A. Blijlevens, Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls, Jürgen Finke, Nicolaas Petrus Michael Schaap, Andrius Zucenka, Stephan Metzelder, Edgar Jost, Zinaida Perić, Fabio Forghieri, Bernadino Allione, Maurizio Martelli, Anna Paola Iori, Sebastian Wittnebel, Andrea Mengarelli, Annalisa Imovilli, Attilio Olivieri, Bernard José Marie De Prijck, Marjolein W.M. van der Poel, Christian Junghanß, Helmut Rainer Salih, Agostino Tafuri, José Eduardo Guimarães, Maurizio Musso, Paolo De Fabritiis, Patrice Chevallier, Dominik Luc Selleslag, Nicola Cascavilla, Zwi Berneman, Aurélie Jaspers, Eliana Zuffa, Gaëtan Vanstraelen, Giuseppe Visani, Maria Louisa Henriëtte Cuijpers, Ann De Becker, Anna Maria Mianulli, Björn Hackanson, Georgi Georgiev Mihaylov, Giovanni Martinelli, Stefania Paolini, Pier Luigi Zinzani, Martin Henkes, Haifa Kathrin Al-Ali, Paul La Rosée, Anna Chierichini, Laura Cudillo, Giorgina Specchia, Njetočka Gredelj Šimec, Silvana Franca Capalbo, Giuseppina Spinosa, Stefano Molica, Susan Dorothé de Jonge-Peeters - The Lancet Haematology 2023 cited by 37

  16. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

    Authors: Jan‐Niklas Eckardt, Marius Bill, Christian Rausch, Klaus H. Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Utz Krug, Bernhard Wörmann, Wolfgang Hiddemann, Dennis Görlich, Cristina Sauerland, Björn Steffen, Hermann Einsele, Andreas Neubauer, Andreas Burchert, Kerstin Schäfer‐Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Leo Ruhnke, Johannes Schetelig, Jan Moritz Middeke, Hubert Serve, Claudia D. Baldus, Uwe Platzbecker, Carsten Müller‐Tidow, Martin Bornhäuser, Tobias Herold, Christian Thiede, Christoph Röllig - Leukemia 2023 cited by 36

  17. Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer

    Authors: Elisabeth Maurer, Friederike Eilsberger, Sabine Wächter, Jorge Riera Knorrenschild, Anika Pehl, Katharina Holzer, Andreas Neubauer, Markus Luster, Detlef K. Bartsch - European Archives of Oto-Rhino-Laryngology 2023 cited by 33

  18. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

    Authors: Martin Bornhäuser, Joachim Kienast, Rudolf Trenschel, Andreas Burchert, Ute Hegenbart, Michael Stadler, H. Baurmann, Kerstin Schäfer‐Eckart, Ernst Holler, Nicolaus Kröger, Christoph Schmid, H. Einsele, Michael Kiehl, Wolfgang Hiddemann, Rainer Schwerdtfeger, Stefanie Buchholz, Peter Dreger, Andreas Neubauer, Wolfgang E. Berdel, Gerhard Ehninger, Dietrich W. Beelen, Johannes Schetelig, Matthias Stelljes - The Lancet Oncology 2012 cited by 272

  19. axl , a Transforming Gene Isolated from Primary Human Myeloid Leukemia Cells, Encodes a Novel Receptor Tyrosine Kinase

    Authors: John P. O’Bryan, Roy A. Frye, Patricia C. Cogswell, Andreas Neubauer, Barry Kitch, Carol Prokop, Rafael Espinosa, Michelle M. Le Beau, H. Shelton Earp, Edison T. Liu - Molecular and Cellular Biology 1991 cited by 230

  20. High-risk additional chromosomal abnormalities at low blast counts herald death by CML

    Authors: Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, Markus Pfirrmann, Lida Kalmanti, Sébastien Rinaldetti, Katharina Kohlbrenner, Claudia Haferlach, Brigitte Schlegelberger, Alice Fabarius, Wolfgang Seifarth, Birgit Spieß, Patrick Wuchter, Stefan W. Krause, Hans‐Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, Christoph Nerl, Aloïs Gratwohl, Gabriela M. Baerlocher, Andreas Burchert, Tim H. Brümmendorf, Jörg Hasford, Andreas Hochhaus, Susanne Saußele, Michele Baccarani, for the SAKK and the German CML Study Group, Ludwig Fischer von Weikersthal, Markus Hahn, Günter Schlimok, Dietmar Reichert, Jan Janßen, Uwe M. Martens, Peter Majunke, Peter Reichert, Kai Neben, Stefan Korsten, Ch. Scholz, Bernd Oldenkott, Jörg Heßling, D. Kingreen, Christian Sperling, C. Schelenz, I. W. Blau, A. Urmersbach, W. D. Ludwig, Philipp le Coutre, R. Arnold, Maike de Wit, Antonio Pezzutto, E. Schäfer, Roland Schroers, A. Lochter, Dirk Behringer, Y. Ko, St. Weidenhöfer, Walter Verbeek, Peter Brossart, Guido Trenn, W Pommerien, J. Krauter, G. Döering, H. Munzinger, C. Diekmann, Bernd Hertenstein, Sebastian Stier, F. Möller-Faßbender, Mathias Hänel, T. Zöller, C. Lamberti, Babette Koch, A. Henzel, Siegfried Wagner, A. Schmalenbach, M. Hoffknecht, Gerhard Ehninger, Alexander Kiani, Thomas Illmer, Carlo Aul, Michael Flaßhove, F. Henneke, M. Simon, Lothar Müller, Heiko Becker, R. F. Janz, Michael J. Eckart, Roland J. Fuchs, Frank Schlegel, Mohammad Amen Wattad, R. Rudolph, Dietrich W. Beelen, A Lindemann, D. Linck, Wassman, Elke Jäger, Salah‐Eddin Al‐Batran, T Reiber, Cornelius F. Waller, Heinz‐Gert Hoeffkes, L.S. Schulz and 154 more - Leukemia 2020 cited by 92

  21. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

    Authors: Jan‐Niklas Eckardt, Friedrich Stölzel, Desireé Kunadt, Christoph Röllig, Sebastian Stasik, Lisa Wagenführ, Korinna Jöhrens, Friederike Kuithan, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Ralph Naumann, Björn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schäfer‐Eckart, Christoph Schliemann, Stefan W. Krause, Regina Herbst, Mathias Hänel, Maher Hanoun, Ulrich Kaiser, Martin Kaufmann, Zdeněk Ráčil, Jiřı́ Mayer, Frank Kroschinsky, Wolfgang E. Berdel, Gerhard Ehninger, Hubert Serve, Carsten Müller‐Tidow, Uwe Platzbecker, Claudia D. Baldus, Johannes Schetelig, Martin Bornhäuser, Christian Thiede, Jan Moritz Middeke - Journal of Hematology & Oncology 2022 cited by 59

  22. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

    Authors: Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen A. Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Récher, Sung‐Soo Yoon, Yoshinobu Maeda, Naoko Hosono, Masahiro Onozawa, Takayasu Kato, Hee‐Je Kim, Nahla Hasabou, Rishita Nuthethi, Ramón V. Tiu, Mark J. Levis - Transplantation and Cellular Therapy 2022 cited by 39

  23. Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness

    Authors: Allan Feng, Emily Yang, A. R. Moore, Shaurya Dhingra, Sarah E. Chang, Xihui Yin, Ruoxi Pi, Elisabeth Mack, Sara Völkel, Reinhard Geßner, Margrit Gündisch, Andreas Neubauer, Harald Renz, Sotirios Tsiodras, Paraskevi C. Fragkou, Adijat Asuni, Joseph E. Levitt, Jennifer G. Wilson, Michelle Leong, Jennifer H. Lumb, Rong Mao, Kassandra Pinedo, Jonasel Roque, Christopher M. Richards, Mikayla A. Stabile, Gayathri Swaminathan, Maria Salagianni, Vasiliki Triantafyllia, Wilhelm Bertrams, Catherine A. Blish, Jan E. Carette, Jennifer Frankovich, Eric Meffre, Kari C. Nadeau, Upinder Singh, Taia T. Wang, Eline T. Luning Prak, Susanne Herold, Evangelos Andreakos, Bernd Schmeck, Chrysanthi Skevaki, Angela J. Rogers, Paul J. Utz - JCI Insight 2023 cited by 28

  24. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

    Authors: Lida Kalmanti, Susanne Saußele, Michael Lauseker, M. C. Muller, Christian Dietz, Linda Heinrich, Benjamin Hanfstein, Ulrike Proetel, Alice Fabarius, Stefan W. Krause, Sébastien Rinaldetti, Jolanta Dengler, Christiane Falge, Elisabeth Oppliger Leibundgut, Andreas Burchert, Andreas Neubauer, Lothar Kanz, Frank Stegelmann, Michael Pfreundschuh, Karsten Spiekermann, Christof Scheid, Markus Pfirrmann, Andreas Hochhaus, Joerg Hasford, R. Hehlmann, for the SAKK and the German CML Study-Group - Leukemia 2015 cited by 274